Navigation Links
Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone

at was statistically worse than that observed in the pixantrone-treated mice. In addition, mortality ranged from 40 to 68 percent in mice receiving two cycles of doxorubicin to 68 percent in mice receiving two cycles of mitoxantrone. In mice receiving two cycles of pixantrone, the mortality rate was 0 percent.

Pixantrone in Clinical Studies

There are currently two clinical studies of pixantrone in aggressive NHL patients, including a phase III single agent trial, known as EXTEND and a phase II/III combination study, known as RAPID. The EXTEND trial explores the role of single agent treatment as a salvage regimen in patients with relapsed aggressive NHL who have failed at least two prior treatment regimens. Patients are randomized to receive either pixantrone or another single-agent drug of physician's choice currently used for the treatment of this patient population. An interim look is planned for the summer of 2007.

The RAPID trial is a first-line randomized phase II/III study of the CHOP-R versus CPOP-R in previously untreated aggressive NHL patients. The study is evaluating replacing doxorubicin in the standard CHOP-R combination regimen (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) with pixantrone as part of the CPOP-R regimen (cyclophosphamide, pixantrone, vincristine, prednisone, and rituximab). The objective of the study is to demonstrate similar objective response rates as the standard doxorubicin-based therapy with significantly less severe cardiac toxicities and other doxorubicin-related toxicities on the CPOP-R arm of the study. A total of 280 patients are expected to be enrolled.

The Company is awaiting feedback from the FDA on the design of a phase III trial of pixantrone for patients with indolent NHL. The trial, PIX303, will examine the complete remission rates and time to disease progression for the combination regimen of fludarabine, pixantrone and rituximab (FP-R) compared to the combination of
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:5/21/2013)... , May 21, 2013  Cephasonics, ... platform, today announced the introduction of the ... complete network-based communications with all cQuest Ultrasound™ ... embedded-ultrasound technology, including this new capability, at ... Paulo, Brazil from May 21-24.  ...
(Date:5/21/2013)... 2013 iHealth Lab Inc., a pioneer ... healthcare products and a powerful integrated mobile app ... of two new fitness products to its existing ... the Wireless Pulse Oximeter and Wireless Activity and ... iHealth Lab is also excited ...
(Date:5/21/2013)... Hurel Corporation ("Hurel"), a world-leading provider of ... today announced the appointment of James S. ... of Directors. Dr. MacDonald is the former Executive Vice ... ("SPRI"), which was the pharmaceutical development arm of Schering ... in 2009. Over a career that has ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2iHealth Lab adds new products and partners to mobile personal healthcare offering 2iHealth Lab adds new products and partners to mobile personal healthcare offering 3Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2
... Cardica, Inc. (Nasdaq: CRDC ) ... General Surgery at the Red Cross Hospital Clementinenhaus, ... laparoscopic procedures using Cardica,s, proprietary Microcutter XPRESS™ 30 ... several sigmoidectomies, an appendectomy and a small intestinal ...
... , For the fourth year, the Fondation,Médéric ... for evidence-based psychosocial,interventions for people with dementia and their ... care and share best,practices. Applications can be submitted from ... http://www.alz.co.uk/award . Psychosocial research involves or ...
Cached Medicine Technology:Dr. Andreas Kuthe Performs First Laparoscopic Procedures Using Cardica's Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device 2Dr. Andreas Kuthe Performs First Laparoscopic Procedures Using Cardica's Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device 34th Alzheimer's Awards Announced in Search of Global Solutions for Better Dementia Care 2
(Date:5/21/2013)... (PRWEB) May 21, 2013 Everspark Interactive, ... firms, has been growing rapidly over the past year ... was hired to spearhead interactive marketing efforts for Kids ... , Everspark started as a local effort, specializing ... guiding search traffic to a company's website. The company ...
(Date:5/21/2013)... May 21, 2013 Romio , ... with trusted services & businesses, announced today that it ... Medical Care. , Emergency Medical Care is located in ... 24 hours a day. The guarantee of seeing ... a promising resource for the neighborhood and a great ...
(Date:5/21/2013)... Alan Mozes HealthDay Reporter , , MONDAY, ... used by millions of people with chronic obstructive ... cardiovascular complications among older patients, a new large ... patients over age 65 who are prescribed long-acting ... beta-agonists (such as Serevent). Both medications are commonly ...
(Date:5/21/2013)... effects of poorly controlled asthma symptoms on sleep ... been confirmed in a new study. , ... and school absences are important indicators of asthma ... to explore the associations between asthma, sleep quality, ... using both objective and subjective measures," said principal ...
(Date:5/21/2013)... After the success of its inaugural 1,000 lb. Meltdown ... Boot Camp Goderich will be hosting its 2nd Annual 1,000 ... fitness center located at 199 Anglesea Street Goderich, Ontario. ... is to inspire and motivate local community residents to lose ... fee to participate is discounted to $40 for the 28-day ...
Breaking Medicine News(10 mins):Health News:Everspark Named Interactive Marketing Company for Kids II 2Health News:Romio Announces Mini Video Series Featuring Local Business Emergency Medical Care 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3Health News:Asthma symptoms impair sleep quality and school performance in children 2Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3
... (BRONX, NY) Researchers at the Albert Einstein College ... first time that cancers can be successfully treated by ... published in the October 31 issue of PloS One, ... virus-infected cells before they turn cancerous. , The Einstein ...
... BioMed Realty Trust, Inc.,(NYSE: BMR ) today announced ... 30, 2007 after the market closes on Wednesday, November ... Officer, and Kent Griffin,Chief Financial Officer, will host an ... November 8, 2007 to discuss the company,s,financial results and ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) announced today ... conferences during which Mike Grey, president & chief,executive officer ... Company,s oncology pipeline. The conference information is as,follows: ... at 9:00 AM Pacific Daylight ...
... 30 PharmAthene, Inc., a leading,biodefense company specializing ... chemical and biological terrorism,announced today that it is ... /,Acumen BioFin 9th Annual Healthcare Conference on Tuesday, ... for the Company will be David P.,Wright, President ...
... LOS ANGELES Healthcare providers have observed it for years ... life while battling their cancer live longer. Now, a ... with locally advanced non-small cell lung backs that observation. ... other classic predictors of survival. , In the past, weve ...
... Virus Shows Promise as Metastatic Cancer Treatment , ... and can differentiate between normal and cancerous cells. The ... cancers, such as small-cell lung cancer. , Cancer-killing viruses ... therapies for localized cancer. But so far their success ...
Cached Medicine News:Health News:Einstein scientists treat cancer as an infectious disease -- with promising results 2Health News:Einstein scientists treat cancer as an infectious disease -- with promising results 3Health News:BioMed Realty Trust to Report 2007 Third Quarter Results 2Health News:SGX Pharmaceuticals to Present at Three Upcoming Investor Conferences 2Health News:Quality of life: most important predictor of survival for advanced NSCLC patients 2Health News:Other highlights in the Oct. 30 JNCI 2Health News:Other highlights in the Oct. 30 JNCI 3Health News:Other highlights in the Oct. 30 JNCI 4
Long-Sleeve Bolero for targeted compression in the upper arms, upper back and shoulder areas. Plush-shielded hook and eye front closure for comfort and convenient application....
Velcro® closure, uniform contour compression, available as 9" and 12" bands for abdominal support, 9" can be used as a breast wrap....
Sub Pectoral Breast Augmentation Wrap...
CDIs Ultra-Comfort Bra™ is designed with special single needle stitching that places the cup seams away from critical surgical sites....
Medicine Products: